Amylyx Pharmaceuticals Inc (AMLX) Stock Price, Quote & News

Company Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of so...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 682 0917

Website: amylyx.com

Address:

55 Cambridge Parkway, Suite 6W, Cambridge, United States

LoveRetailFroth Mar. 17 at 1:47 PM

$ARBE Good Morning ☕️ About Time🚀 $RXRX $SANA $AMLX

0 · Reply

LoveRetailFroth Mar. 16 at 3:50 PM

$AMLX How is my 💎 of all 💎 s doing? 😘 $40 🚀

0 · Reply

LoveRetailFroth Mar. 13 at 1:39 PM

$SANA Good Morning ☕️ $RXRX $ARBE $AMLX

1 · Reply

ajmore Mar. 12 at 2:53 PM

$AMLX from Tuesday, presentation at Leerink Target price reiterated 20 and Buy! today down on oil, index selling. Pharma stocks are seen as shelter and once index selling eases buyers will step in pharma big time. all intact! last and final batch of participants joined the trial more than 3 weeks ago...good sign!

0 · Reply

SilentBull69 Mar. 12 at 1:35 PM

$AMLX What did I miss…?

1 · Reply

LoveRetailFroth Mar. 11 at 2:15 PM

$VVPR Good Morning ☕️ $RARE $TEMT $AMLX $DTIL

0 · Reply

vjtweet Mar. 11 at 2:52 AM

$AMLX 6 month range likely to breakout soon. Keep it on watch list. No position yet.

0 · Reply

ajmore Mar. 5 at 3:17 PM

$AMLX Wainwright raises target to 34usd !

1 · Reply

ajmore Mar. 5 at 2:42 PM

$AMLX drop now is most likely broker selling the shares surrendered for tax. ~80k shares in total! half way there! if i am right it will bounce back up and continue north. lets see.

0 · Reply

BillionerOfKing Mar. 4 at 6:22 PM

$AMLX Current Stock Price: $14.88 Contracts to trade: $15.0 AMLX Mar 20 2026 Call Entry: $0.10 Exit: $0.14 ROI: 43% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

Mar 3, 2026, 4:32 PM EST - 14 days ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript

Mar 3, 2026, 7:00 AM EST - 15 days ago

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 9:00 AM EST - 19 days ago

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 9:00 AM EST - 21 days ago

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Jan 29, 2026, 5:05 PM EST - 6 weeks ago

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Jan 8, 2026, 7:00 AM EST - 2 months ago

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

Dec 5, 2025, 9:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

Dec 3, 2025, 7:53 PM EST - 3 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 13, 2025, 2:40 PM EST - 4 months ago

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Nov 6, 2025, 2:06 PM EST - 4 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 4 months ago

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 4 months ago

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Oct 30, 2025, 9:00 AM EDT - 4 months ago

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 27, 2025, 12:20 PM EDT - 5 months ago

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 16, 2025, 4:40 PM EDT - 5 months ago

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

Sep 10, 2025, 12:06 AM EDT - 6 months ago

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Sep 9, 2025, 4:01 PM EDT - 6 months ago

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 8, 2025, 9:01 PM EDT - 6 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 6:14 PM EDT - 7 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 27, 2025, 7:28 AM EDT - 7 months ago

Amylyx to stop development of rare brain disorder drug after trial failure

Aug 27, 2025, 7:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Aug 26, 2025, 9:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 7, 2025, 10:35 PM EDT - 7 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 9:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 21, 2025, 4:26 PM EDT - 8 months ago

Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential

Jul 14, 2025, 2:15 PM EDT - 8 months ago

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

Jul 13, 2025, 5:00 PM EDT - 8 months ago

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Jul 8, 2025, 7:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

Jun 24, 2025, 2:59 PM EDT - 9 months ago

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market

Jun 17, 2025, 10:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 15, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

Jun 12, 2025, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

Jun 8, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Jun 3, 2025, 7:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Jun 1, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

May 29, 2025, 10:05 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

May 27, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

May 25, 2025, 10:00 AM EDT - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 21, 2025, 7:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 12, 2025, 7:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

May 11, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

May 10, 2025, 11:19 AM EDT - 11 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

LoveRetailFroth Mar. 17 at 1:47 PM

$ARBE Good Morning ☕️ About Time🚀 $RXRX $SANA $AMLX

0 · Reply

LoveRetailFroth Mar. 16 at 3:50 PM

$AMLX How is my 💎 of all 💎 s doing? 😘 $40 🚀

0 · Reply

LoveRetailFroth Mar. 13 at 1:39 PM

$SANA Good Morning ☕️ $RXRX $ARBE $AMLX

1 · Reply

ajmore Mar. 12 at 2:53 PM

0 · Reply

SilentBull69 Mar. 12 at 1:35 PM

$AMLX What did I miss…?

1 · Reply

LoveRetailFroth Mar. 11 at 2:15 PM

$VVPR Good Morning ☕️ $RARE $TEMT $AMLX $DTIL

0 · Reply

vjtweet Mar. 11 at 2:52 AM

$AMLX 6 month range likely to breakout soon. Keep it on watch list. No position yet.

0 · Reply

ajmore Mar. 5 at 3:17 PM

$AMLX Wainwright raises target to 34usd !

1 · Reply

ajmore Mar. 5 at 2:42 PM

$AMLX drop now is most likely broker selling the shares surrendered for tax. ~80k shares in total! half way there! if i am right it will bounce back up and continue north. lets see.

0 · Reply

BillionerOfKing Mar. 4 at 6:22 PM

0 · Reply

ajmore Mar. 4 at 6:29 AM

$AMLX notes from the conf call:" management's tone was more assertive on progress and readiness.", "cmo added that participation in the open-label extension is peogressing well".l, "Lucidity, pahse 3 trial, completed recruiting and data", "company expects to publish study data in q3, inline with what they said in December".

0 · Reply

ajmore Mar. 3 at 4:29 PM

$AMLX sec rule 201 means short only on the uptic and its in effect for today and tomorrow.

1 · Reply

ajmore Mar. 3 at 4:29 PM

$AMLX sec rule 201! now lets get that fireside chat. *down with the rest of the oversold pharma.

0 · Reply

SilentBull69 Mar. 3 at 4:22 PM

$AMLX Waaaayy oversold here…..wtf

0 · Reply

StocktwitsEarnings Mar. 3 at 2:00 PM

$AMLX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.30 up 45.45% YoY • Amylyx Pharmaceuticals believes its existing cash, cash equivalents, and marketable securities of $317.0 million as of December 31, 2025, will be sufficient to fund operations into 2028.

0 · Reply

StocktwitsEarnings Mar. 3 at 2:00 PM

$AMLX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.30 up 45.45% YoY • Amylyx Pharmaceuticals Inc expects to generate significant losses for the foreseeable future and anticipates increased expenses in connection with planned clinical development activities, but believes existing cash will fund operations into 2028.

0 · Reply

dogfish90ipa Mar. 3 at 1:50 PM

$AMLX Why are they filing for mixed shelf if they have cash through 2028?

1 · Reply

mikesterz7 Mar. 3 at 12:50 PM

$AMLX Q4 2025 Revenue: Not reported for the quarter ($0.00). Q4 2025 EPS: -$0.30, which exceeded analyst expectations of -$0.34. Full Year 2025 EPS: -$1.53, a significant improvement from the -$4.43 per share reported in 2024. Net Loss (Q4): $33.0 million, compared to $37.5 million in Q4 2024. Cash Position: $317.0 million as of December 31, 2025, with expectations for the cash runway to extend into 2028. Pipeline and Business Updates Avexitide (PBH): Recruitment for the Phase 3 LUCIDITY trial is complete, with top-line data expected in Q3 2026 and a potential commercial launch in 2027. AMX0035: Continued development for Wolfram syndrome and Progressive Supranuclear Palsy (PSP). Operating Expenses: R&D and SG&A expenses declined compared to 2024, reflecting reduced spending on the withdrawn ALS drug and a focus on new initiatives. Amylyx

0 · Reply

erevnon Mar. 3 at 11:07 AM

Stifel initiates coverage on Amylyx Pharmaceuticals $AMLX at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

DARKP00L Mar. 3 at 10:04 AM

$AMLX 04:35 on Mar. 03 2026 Stifel Initiates Coverage On Amylyx Pharmaceuticals with Buy Rating, Announces Price Target of $21 #tradeideas

0 · Reply

ajmore Mar. 3 at 7:21 AM

$AMLX Stifel initiate coverage with a buy and target 21. presenting at TD Cowen today at 11:10 ET (fireside chat).

0 · Reply

ajmore Mar. 2 at 8:16 AM

$NVO $PFE pharma shopping day! any initial drops get followed by long term investors. orphan drugs should be resilient like $AMLX ...

0 · Reply

Market Cap	1.55B
Revenue (ttm)	0.00
Net Income (ttm)	-144.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	520,000
Avg Vol	1,299,392
Day's Range	N/A - N/A
Shares Out	110.54M
Stochastic %K	44%
Beta	-0.31
Analysts	Strong Sell
Price Target	$22.30